Klaus Cichutek

from Wikipedia, the free encyclopedia

Klaus Cichutek (born February 26, 1956 in Recklinghausen ) is a German biochemist and adjunct professor of biochemistry at the Johann Wolfgang Goethe University in Frankfurt am Main . Since 2009 he has been President of the Paul Ehrlich Institute , Federal Institute for Vaccines and Biomedical Medicines.

Life

Klaus Cichutek grew up in Oer-Erkenschwick . From 1976 to 1981 he studied chemistry with a major in biochemistry. In 1984 he was with a thesis in biochemistry at the Institute of Biochemistry at the University of William of Westphalia in Muenster doctorate . From 1985 to 1988, he did a research stay at the Department of Molecular Biology and Virus Laboratory at the University of California, Berkeley , which was funded in the first two years by a training grant from the German Research Foundation.

Cichutek has been working as a scientist at the Paul Ehrlich Institute since 1988. In 1992 he received his habilitation and in 1998 he was appointed adjunct professor in the department of biochemistry, chemistry and pharmacy at the Goethe University in Frankfurt am Main. From 1988 to 1994 he was head of the molecular biology research group and from 1994 to 2011 head of the medical biotechnology department responsible for regulatory and research tasks in the field of gene and cell therapy .

In 1999 Cichutek took over the role of permanent representative of the President of the Paul Ehrlich Institute. From October 31, 2001 to November 30, 2009 he was Vice President and since December 1, 2009 he has been President of the Paul Ehrlich Institute.

In the period from 2000 to 2010 Cichutek was chairman of the somatic gene therapy commission of the scientific advisory board of the German Medical Association . From 2003 to 2010 he was chair of the Gene Therapy Working Party (GTWP) of the Committee for Medicinal Products (CHMP) of the European Medicines Agency (EMA). From 2004 to 2010 he was co-chair of the ICH Gene Therapy Discussion Group of the International Conference on Harmonization of Pharmaceutical Requirements for Human Use .

He was a member of the board of the European Society of Gene and Cell Therapy (ESGCT) from 2005 to 2010. Since 2010 Cichutek has been a board member of the working group of departmental research institutions . In 2012 he became a founding member and PDU ( Product Development Unit ) coordinator of the German Center for Infection Research ( DZIF ) and a member of the Loewe Center for Cell and Gene Therapy in Frankfurt am Main.

From 2011 to February 2014, Cichutek was co-chair of the Benchmarking of European Medicines Agencies (BEMA) group of the Heads of Medicines Agencies (HMA) group. From March 2014 to February 2018 he was Chairman of the HMA Management Group , to which he was elected in February 2014.

Since June 2012 he has been a member of the WHO Expert Advisory Panel on Biological Standardization , of which he was elected chairman in 2016 and 2017, and since February 2014 he has been a member of the Product Development for Vaccines Advisory Committee (PD-VAC) of the WHO . Cichutek is the author or co-author of more than 110 publications in international science journals.

research

Cichutek's research interests include biomedical drugs (including drugs for advanced therapies and DNA / vector vaccines), gene therapy (including viral vectors, stem cell gene transfer ) and retrovirology with a focus on HIV / SIV immunopathogenesis and AIDS

After investigations on the cellular cancer precursor gene proto-ras carrying sarcoma viruses in mice, Klaus Cichutek examined the non- pathogenic infection of African green monkeys with their simian immunodeficiency virus. Based on the formation of HIV-1 variants in humans, he demonstrated the initial infection with a single biological virus clone. In gene therapy he succeeded in developing a series of retroviral pseudotype vectors as well as retro and lentiviral vectors for targeted gene transfer into selected cell types, so-called cell targeting vectors. He demonstrated the possibility of analyzing human cells in the laboratory and selected cell types in vivo, i.e. H. in the body of mice to modify with these vectors. To do this, he built antibody domains into the vector envelope that recognize certain surface molecules on cells, so that the vectors transfer their therapeutic genes via these surface molecules into the genome of the body cells. In recent years, the research of vector vaccines based on the measles vaccine virus and the testing of CAR-T cells in animal models have been the focus of his research.

Fonts (selection)

  • SIV grows unchanged in human cells . Werner A, Baier M, Cichutek K, Kurth R. Nature. 1990 Mar 8; 344 (6262): 113. DOI: 10.1038 / 344113a0
  • Development of a quasispecies of human immunodeficiency virus type 1 in vivo . Cichutek K, Merget H, Norley S, Linde R, Kreuz W, Gahr M, Kurth R. Proc Natl Acad Sci US A. 1992 Aug 15; 89 (16): 7365-9. PMID 1502146
  • Lack of immune suppression in SIV-infected natural hosts . Cichutek K, Norley S. AIDS. 1993; 7 Suppl 1: S25-35. Review. PMID 8395860
  • Development of transforming function during transduction of proto-ras into Harvey sarcoma virus . Lang M, Treinies I, Duesberg PH, Kurth R, Cichutek K. Proc Natl Acad Sci US A. 1994 Jan 18; 91 (2): 654-8. PMID 8290577
  • Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells . Schnierle BS, Stitz J, Bosch V, Nocken F, Merget-Millitzer H, Engelstädter M, Kurth R, Groner B, Cichutek K. Proc Natl Acad Sci US A. 1997 Aug 5; 94 (16): 8640-5. PMID 9238030
  • The U3 promoter and the nef gene of simian immunodeficiency virus (SIV) smmPBj1.9 do not confer acute pathogenicity upon SIVagm . Wagener S, Dittmar MT, Beer B, König R, Plesker R, Norley S, Kurth R, Cichutek K. J Virol. 1998 Apr; 72 (4): 3446-50. PMID 9525679
  • Retroviral cell targeting vectors . Buchholz CJ, Stitz J, Cichutek K. Curr Opin Mol Ther. 1999 Oct; 1 (5): 613-21. Review. PMID 11249668
  • European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements . Robertson JS, Cichutek K. Dev Biol (Basel). 2000; 104: 53-6. PMID 11713824
  • A novel lentivirus vector derived from apathogenic simian immunodeficiency virus . Stitz J, Mühlebach MD, Blömer U, Scherr M, Selbert M, Wehner P, Steidl S, Schmitt I, König R, Schweizer M, Cichutek K. Virology. 2001 Dec 20; 291 (2): 191-7. DOI: 10.1006 / viro.2001.1183
  • Human CD4 + T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR . Sun Y, Song M, Jäger E, Schwer C, Stevanovic S, Flindt S, Karbach J, Nguyen XD, Schadendorf D, Cichutek K. Clin Cancer Res. 2008 Jul 1; 14 (13): 4306-15. doi: 10.1158 / 1078-0432.CCR-07-4849 .
  • Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer? Buchholz CJ, Mühlebach MD, Cichutek K. Trends Biotechnol. 2009 May; 27 (5): 259-65. doi: 10.1016 / j.tibtech.2009.02.002 . Epub 2009 Mar 25th Review.
  • Adherens junction protein nectin-4 is the epithelial receptor for measles virus . Mühlebach MD, Mateo M, Sinn PL, Prüfer S, Uhlig KM, Leonard VH, Navaratnarajah CK, Frenzke M, Wong XX, Sawatsky B, Ramachandran S, McCray PB Jr, Cichutek K, von Messling V, Lopez M, Cattaneo R. Nature. 2011 Nov 2; 480 (7378): 530-3. doi: 10.1038 / nature10639 .
  • A global regulatory science agenda for vaccines . Elmgren L, Li X, Wilson C, Ball R, Wang J, Cichutek K, Pfleiderer M, Kato A, Cavaleri M, Southern J, Jivapaisarnpong T, Minor P, Griffiths E, Son Y, Wood D. Vaccine. 2013 Apr 18; 31 Suppl 2: B163-75. doi: 10.1016 / j.vaccine.2012.10.117 . Review
  • DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety . Friedrich K, Hanauer JR, Prüfer S, Münch RC, Völker I, Filippis C, Jost C, Hanschmann KM, Cattaneo R, Peng KW, Plückthun A, Buchholz CJ, Cichutek K, Mühlebach MD. Mol Ther. 2013 Apr; 21 (4): 849-59. doi: 10.1038 / mt.2013.16 . Epub 2013 Feb 5.
  • Special considerations for the regulation of biological medicinal products in individualized medicine. More than stratified medicine . Müller-Berghaus J, Volkers P, Scherer J, Cichutek K. Federal Health Gazette Health Research Health Protection. 2013 Nov; 56 (11): 1538-44. doi: 10.1007 / s00103-013-1826-y . German
  • A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform . Malczyk AH, Kupke A, Prüfer S, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, Eldin HS, Schmidt J, Vergara-Alert J, Süzer Y, Seifried J, Hanschmann KM, Kalinke U, Herold S, Sahin U, Cichutek K, Waibler Z, Eickmann M, Becker S, Mühlebach MD.J Virol. 2015 Nov; 89 (22): 11654-67. doi: 10.1128 / JVI.01815-15 . Epub 2015 Sep 9.
  • Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2 / neu or EpCAM as target receptors . Hanauer JR, Gottschlich L, Riehl D, Rusch T, Koch V, Friedrich K, Hutzler S, Prüfer S, Friedel T, Hanschmann KM, Münch RC, Jost C, Plückthun A, Cichutek K, Buchholz CJ, Mühlebach MD. Mol Ther Oncolytics. 2016 Feb 24; 3: 16003. doi: 10.1038 / mto.2016.3 eCollection 2016.

Web links

Individual evidence

  1. ↑ PEI press release of November 20, 2009: "Federal Minister of Health Rösler visits the Paul-Ehrlich-Institut congratulates Prof. Cichutek on his appointment as President of the Paul-Ehrlich-Institut."
  2. ^ Paul Ehrlich Institute: Prof. Dr. Klaus Cichutek (Curriculum vitae) , accessed on August 14, 2020.
  3. ↑ European Medicines Agency: Klaus Cichutek
  4. ^ WHO Product Development for Vaccines Advisory Committee
  5. ↑ CV Klaus Cichutek
personal data
SURNAME Cichutek, Klaus
BRIEF DESCRIPTION German biochemist and President of the Paul Ehrlich Institute
DATE OF BIRTH February 26, 1956
PLACE OF BIRTH Recklinghausen